A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

Not specified

Conditions
HIV InfectionsChickenpox
Interventions
DRUG

Netivudine

DRUG

Acyclovir

Trial Locations (25)

27262

Jordon Diagnostics and Research Inc, High Point

28401

Hanover Med Specialists, Wilmington

35211

Simon - Williamson Clinic, Birmingham

35234

SORRA / NC Research Ctr, Birmingham

37232

Vanderbilt Med Ctr, Nashville

52001

Med Associates Clinic, Dubuque

53215

Med Consultants LTD, Milwaukee

54501

Rhinelander Med Ctr, Rhinelander

63110

Washington Univ, St Louis

70121

Oschner Clinic, New Orleans

75219

N Texas Ctr for AIDS & Clin Rsch, Dallas

77054

MacGregor Med Association, Houston

77058

Univ TX Med Branch, Nassau Bay

85724

Univ of Arizona / Univ Med Ctr, Tucson

87110

New Mexico Med Group, Albuquerque

90048

Cedars Sinai Med Ctr, Los Angeles

94063

AIDS Community Research Consortium, Redwood City

94086

Sunnyvale Med Clinic, Sunnyvale

94109

Saint Francis Mem Hosp, San Francisco

97201

Oregon Health Sciences Univ, Portland

97401

Oregon Research Group, Eugene

98405

Infections Ltd / Physicians Med Ctr, Tacoma

06611

Clinical Research Consultants, Trumbull

02908

Roger Williams Med Ctr, Providence

02909

Silver Lake Med Inc, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Glaxo Wellcome

INDUSTRY

NCT00002315 - A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems | Biotech Hunter | Biotech Hunter